Access cutting-edge pancreatic cancer treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.
Access pancreatic cancer specialists in Washington Dc at no cost
This study follows strict safety protocols and ethical guidelines
All study-related pancreatic cancer treatment provided free
The goal of this clinical trial is to test the safety and tolerability of anti-CD38 monoclonal antibody (mAb), daratumumab, in combination with KRAS vaccine (Targovax TG-01/Stimulon QS-21) when given with anti-PD-1 (programmed cell death protein 1) mAb (nivolumab) in patients with advanced non-small cell lung cancer (NSCLC) or pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: * How well does daratumumab and nivolumab, when given with a vaccine, control or stop t
Sponsor: Georgetown University
Check if you qualify for this pancreatic cancer clinical trial in Washington Dc, DC
If you're searching for pancreatic cancer treatment options in Washington Dc, DC, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pancreatic cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.